Diaceutics Contributes to the Evolving Dialogue on Precision Medicine and Companion Diagnostics in Its Editorial Published in Precision Cancer Medicine (PCM) March 2019 | Diaceutics

Diaceutics Contributes to the Evolving Dialogue on Precision Medicine and Companion Diagnostics in Its Editorial Published in Precision Cancer Medicine (PCM) March 2019

March 15th, 2019

Diaceutics helps raise awareness of the need for better diagnostic testing in the editorial “It’s all about diagnostics, stupid!” published in the March 2019 issue of Precision Cancer Medicine (PCM) accessible here.1 The editorial reflects Diaceutics’ perspective through the lens of its non-profit organization, Precision Medicine (PM) Connective, which was created to improve diagnostic testing and benefit patients.

The patient journey, from initial symptom to appropriate diagnosis, is all too often populated with inappropriate testing and subsequent diagnostic errors, delaying the start of appropriate treatment for months to potentially years. Limited availability of and access to diagnostic tests contributes to those diagnostic errors,2 which are quite commonplace. According to diagnostic patient journey research, most patients can expect to endure at least one diagnostic error throughout their lives.3 In 2016, the World Health Organization (WHO) recognized diagnostic errors as a priority patient safety concern in primary care.2 The WHO recommended improving patient access to high-quality diagnostic testing services (eg, radiology/laboratory) in the primary care setting.

In the Precision Cancer Medicine editorial, Diaceutics contributes to the ongoing dialogue on improving diagnostic testing practices. Specifically, Diaceutics presents an argument to further repair the “broken testing ecosystem” through patient empowerment and broader access to diagnostic tests in an effort to ultimately improve patient health outcomes.1

Diaceutics is an industry leading data analytics and implementation services provider to the pharmaceutical industry, focused on diagnostic commercialization and the intersection between diagnostics and therapeutic decision-making. In addition to the PM Connective, Diaceutics advocates for patients through international partnerships, including sponsoring World Cancer Day with the Union for International Cancer Control (UICC). The UICC’s “Treatment for All” campaign is based on four essential pillars of cancer treatment and care, including increasing the number of people with access to early detection and accurate cancer diagnosis.4

The editorial, written by Piarella Peralta, Associate Director of Patient Advocacy at PM Connective, can be accessed here.


  1. Peralta P. It’s all about diagnostics, stupid! Precis Cancer Med. 2019;2:6. http://pcm.amegroups.com/article/view/4921/html. Accessed March 13, 2019.
  2. Diagnostic errors: technical series on safer primary care. Geneva: World Health Organization; 2016. https://apps.who.int/iris/bitstream/handle/10665/252410/9789241511636-eng.pdf;jsessionid=B7EFB45EFC66E43C1E652CFB394CC3B3?sequence=1. Accessed March 8, 2019.
  3. National Academies of Sciences, Engineering, and Medicine. 2015. Improving diagnosis in health care. Washington, DC: The National Academies Press. http://www.nationalacademies.org/hmd/Reports/2015/Improving-Diagnosis-in-Healthcare. Updated October 19, 2019. Accessed March 8, 2019.
  4. Treatment for all. Union for International Cancer Control Web site. https://www.uicc.org/what-we-do/advocacy/treatment-all. Updated February 11, 2019. Accessed March 13, 2019.

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications